← All diseases
Brain and nervous system
Lewy body dementia
Do you want to receive a message when there is new research about Lewy body dementia? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, one sentence appears above each publication explaining what was studied — and you receive a message as soon as there is new research about Lewy body dementia. View what Premium costs.
Publications and studies (1347)
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Clinical Diagnosis and Treatment of Anxiety in Dementia With Lewy Bodies. (2026/06/02) ♡
- Remote, self-administered, smartphone cognitive testing in a registry-based cohort: Feasibility, reliability, and validity findings. (2026/06/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Contributions of the Alzheimer's Disease Neuroimaging Initiative to advancing AD research: a targeted review of recent publications. (2026/06/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Deciphering Freezing of Gait: What Neuropathology Reveals About an Episodic Phenomenon. (2026/06/01) ♡
- Dementia etiology classification using NULISA plasma biomarkers and machine learning. (2026/06/01) ♡
- Spontaneous Isomerization of Tau is Most Prevalent in Alzheimer's Disease. (2026/06/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Contributions of seeding amplification assays to the diagnosis of synucleinopathies]. (2026/06/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Anti-diabetic medications to fight Parkinson's disease and dementia with Lewy bodies: a pilot study. (2026/05/29) ♡
- Age-adjusted neurofilament light chain cutoffs for diagnosing neurodegenerative dementia: a two-threshold machine learning approach. (2026/05/12) ♡
- In vivo-measured Lewy body pathology is associated with neuropsychiatric symptoms across the Alzheimer's disease continuum. (2026/05/01) ♡
- 14-3-3σ up-regulation in the temporal cortex associates with tau pathology and reactive astroglia in Lewy body disorders. (2026/05/01) ♡
- Cutaneous Phosphorylated Alpha-Synuclein in Lewy Body Dementia. (2026/05/01) ♡
- Serum p-tau217 Is a Prognostic Indicator of Cognitive Impairment in Idiopathic REM Sleep Behavior Disorder. (2026/04/01) ♡
- Skin Biopsy for Phosphorylated α-Synuclein in Mild Cognitive Impairment or Dementia Due to Lewy Body Disease in a Convenience Cohort from a Subspecialty Behavioral Neurology Practice. (2026/04/01) ♡
- Distinct associations between body mass index and polyunsaturated fatty acids in dementia with Lewy Bodies and Alzheimer's disease. (2026/04/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Investigations on the effects of SH2B2 on Parkinson's disease based on its in vivo and in vitro neurotoxic model. (2026/03/05) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Nuclear Alpha-Synuclein: Mechanisms and Implications for Synucleinopathies. (2026/03/01) ♡
- Contribution of quantitative I-123-ioflupane SPECT/CT to the differential diagnosis of dementia with lewy bodies. (2026/03/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Emerging nano-derived therapy for the treatment of dementia: a comprehensive review. (2026/03/01) ♡
- Differentiating gait behaviors between early-stage dementia with Lewy bodies and Parkinson's disease. (2026/02/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Characteristics and mechanisms of cognitive impairment in Parkinson disease. (2026/02/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Where do PDD and DLB SYNdromes fit in neuronal alpha-SYNuclein biological frameworks? (2026/02/01) ♡
- Find-DLB: a naturalistic cohort of patients presenting with clinical features of dementia with Lewy bodies to a specialized cognitive clinic. (2026/02/01) ♡
- Sex differences for symptoms prior to dementia onset in people with Lewy body pathology compared to pure Alzheimer's disease pathology. (2026/02/01) ♡
- Extracellular water-to-total body water ratio predicts phenoconversion in REM sleep behavior disorder: A bioimpedance-based cohort study. (2026/02/01) ♡
- The future of clinical trials? Monitoring mobility as an outcome measure in Parkinson's disease: The mobilise-D study. (2026/02/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Do sex differences in dementia with Lewy bodies arise from Alzheimer's disease biological profile? (2026/02/01) ♡
- Symptom diagnosis codes informing under-diagnosis of Lewy body dementia in Medicare beneficiaries from different ethnoracial backgrounds. (2026/02/01) ♡
- Hong Kong Brief Cognitive Test for identifying symptomatic Alzheimer's disease and other types of dementia. (2026/02/01) ♡
- Profiling the Braak progression in Parkinson's disease: a transcriptomics and ML driven identification of progressive biomarker and prognostic ceRNA signature. (2026/01/26) ♡
- A cross-database bibliometric analysis of rapid eye movement sleep behavior disorder in Parkinson's disease research. (2026/01/15) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Unfolding Sequence-Specific Enigma in Monomeric α-Synuclein: Implications for Parkinson's Disease. (2026/01/07) ♡
- Interpeduncular Angle: A Possible Marker to Differentiate Atypical Parkinsonism from Idiopathic Parkinson's Disease. (2026/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Plasma biomarkers in neuropsychiatric syndromes: A narrative review. (2026/01/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. The diagnostic value investigation of blood lipid as biomarker combined with apolipoprotein E genotype in dementia with Lewy bodies. (2026/01/01) ♡
- RETRACTION: α-Synuclein Conformational Antibodies Fused to Penetratin are Effective in Models of Lewy Body Disease. (2026/01/01) ♡
- Prediction of Amyloid Positivity in Lewy Body Disease Using Early-Phase 18 F-FP-CIT PET Images. (2026/01/01) ♡
- Skin-derived α-synuclein strains from PD, DLB, and MSA induce distinct intracellular pathology and neurodegeneration. (2026/01/01) ♡
- A Unified Continuous Staging Framework for Alzheimer's Disease and Lewy Body Dementia via Hierarchical Anatomical Features. (2026/01/01) ♡
- Domain-Adaptive Diagnosis of Lewy Body Disease with Transferability Aware Transformer. (2026/01/01) ♡
- Brain atrophy staging in spinocerebellar ataxia type 3 for clinical prognosis and trial enrichment. (2026/01/01) ♡
- Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Efficacy and Safety of Tsumura Ninjin'yoeito for Loss of Appetite and Apathy in Patients With Alzheimer's Disease or Dementia With Lewy Bodies: A Multicentre, Open-Label, Randomised, Comparative Study. (2026/01/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study (2026-08-10) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM Sleep Behavior Disorder (2026-08-10) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) (2026-08-06) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. MIBG in Aging and Neurologic Disorders (2026-07-30) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis (2026-07-24) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis (2026-07-24) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies (2026-07-10) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies (2026-07-08) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.